Simtra BioPharma Solutions Completes Injectable Manufacturing Expansion in Germany

• Simtra BioPharma Solutions has completed construction of a new injectable manufacturing building at its Halle, Germany campus.

• The expansion adds 150 new jobs and strengthens the company’s CDMO capabilities in sterile injectable drug production.

Simtra BioPharma Solutions, a contract development and manufacturing organisation (CDMO) focused on sterile injectables, has completed construction of a new production building at its Halle, Germany campus. This expansion forms part of the company’s efforts to meet growing global demand for complex injectable therapeutics across Europe and North America.

The new facility adds over 1,800 square metres to the Halle site, increasing the total production area to nearly 12,000 square metres. It also brings the total number of freeze dryers at the site to 15. Freeze drying is essential for maintaining the stability of sensitive drug products. With this new addition, the site will now employ 950 people, including 150 new roles.

The expanded capacity will support fill/finish services for highly potent vials and prefilled syringes—a technology newly introduced at the Halle location. Once operational, Simtra expects strong demand across both new production lines.

“With this expansion in Halle, we are in a great position to help our clients accelerate development of new therapies, such as targeted cancer treatments, and deliver these critical drugs to patients sooner,” said Franco Negron, CEO of Simtra BioPharma Solutions.